The National Medical Insurance Bureau issued a notice announcing the 2022 National Medical Insurance Catalogue, which has passed the preliminary formal examination, involving a total of 344 varieties

"In the future, 'price reduction' may no longer be the only criterion for the success of the national medical insurance access negotiation, if some accurate negotiation models for rare disease drugs can be formed, it may bring greater and more far-reaching significance and impact

"In the future, 'price reduction' may no longer be the only criterion for the success of the national medical insurance access negotiation, if some accurate negotiation models for rare disease drugs can be formed, it may bring greater and more far-reaching significance and impact

Among them, the number of varieties involving rare diseases reached 19, including not only varieties that failed in previous medical insurance negotiations, but also newly listed varieties and old varieties

The child receives intrathecal injection of Nocinazine sodium at Beijing Children's Hospital, courtesy of the

A number of high-profile drugs have been selected

The China Rare Disease Definition Research Report 2021 lists "diseases with a neonatal incidence of less than 1/0,000, a prevalence of less than 1/0,000, and a number of people with a prevalence of less than 140,000" as a rare disease

In 2021, two high-value rare disease drugs successfully entered the medical insurance through the national medical insurance negotiations for the first time, they are the SMA (spinal muscular atrophy) treatment drug Nocinasin sodium injection known as the "sky-high drug", and the Fabre disease treatment drug Ripga (agasactase α concentrated solution for injection).

The Health Times reporter noted that in the list of declared drugs that passed the preliminary examination this year, there are two other treatment drugs

Hu Shanlian, a professor at the School of Public Health of Fudan University, said in an interview with the Health Times reporter that last year's Nosinasin sodium injection that treated SMA successfully entered medical insurance through "soul bargaining", and this year, another SMA treatment drug, Risperlan oral solution, was once again selected for the preliminary review list, in addition to another Fabre disease treatment drug Agasacase β also passed the preliminary review

"This is naturally a great benefit for patients with rare diseases, such as risprolam, which is an oral solution, which is more convenient and less

α

There are many high-value drugs, and the key is to "talk"

There are many high-value drugs, and the key is to "talk"

The Health Times reporter combed and found that among the 19 rare disease drugs involved in the drug list that passed the preliminary review, there were as many as 11 high-value drugs with an annual treatment cost of more than 300,000, such as the high-profile Fabre disease treatment drug injection with agasacse β, with an annual treatment cost of about 1.

Among the 19 rare disease drugs involved in the drug list that passed the preliminary review, there are as many as 11 high-value drugs with an annual treatment cost of more than 300,000, such as the high-profile Fabre disease treatment drug injection agasacse β, with an annual treatment cost of about 1.

"Last year, two high-value rare disease drugs successfully entered the medical insurance list, and whether this year can continue this number is still unknown, but I think that the number of drugs and drug prices that enter the medical insurance list through negotiation is important, but there should be a higher pattern and innovative measures